Relevant bibliographies by topics / Cléo de 5 à 7 / Journal articles
To see the other types of publications on this topic, follow the link: Cléo de 5 à 7.

Journal articles on the topic 'Cléo de 5 à 7'

Author: Grafiati
Published: 4 June 2021
Last updated: 27 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cléo de 5 à 7.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bazgan, Nicoleta. "Cléo de 5 à 7." Historical Journal of Film, Radio and Television 30, no. 1 (2010): 135–37. http://dx.doi.org/10.1080/01439680903577458.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Smyth, Sarah Louise. "Feminist film theory and ‘Cléo from 5 to 7’." Studies in European Cinema 17, no. 3 (2018): 273–75. http://dx.doi.org/10.1080/17411548.2018.1461590.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Herbeck, Mariah Devereux. "Feminist Film Theory and Cléo de 5 à 7 by Hilary Neroni." French Review 90, no. 3 (2017): 241–42. http://dx.doi.org/10.1353/tfr.2017.0354.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pam Fox Kuhlken. "Clarissa and Cléo (En)durée Suicidal Time in Virginia Woolf’s Mrs. Dalloway and Agnès Varda’s Cléo de 5 à 7." Comparative Literature Studies 45, no. 3 (2008): 341–69. http://dx.doi.org/10.1353/cls.0.0031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kuhlken, Pam Fox. "Clarissa And ClÉO (En)DurÉe Suicidal Time In Virginia Woolf's Mrs. Dalloway And AgnÈs Varda's ClÉo De 5 À 7." Comparative Literature Studies 45, no. 3 (2008): 341–69. http://dx.doi.org/10.2307/complitstudies.45.3.0341.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cooke, Dervila. "Cléo and Chloé on the Margins of Parisian Flânerie : Questions of Self and Other in Cléo de 5 à 7 and Chacun cherche son chat." Irish Journal of French Studies 6, no. 1 (2006): 67–85. http://dx.doi.org/10.7173/164913306818438528.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tuncer, Asli Özgen. "Women on the Move: The Politics of Walking in Agnès Varda." Deleuze Studies 6, no. 1 (2012): 103–16. http://dx.doi.org/10.3366/dls.2012.0049.

Full text
Abstract:
This article focuses on images of walking in Agnès Varda's films – Cléo de 5 à 7 (1962), Sans toit ni loi (1985), and Les Plages d’Agnès ( 2008 ). The activity of walking (as urban flânerie, circular travelling or walking backwards) is central to these films, and can be seen as a corporeal practice that not only interweaves striated and smooth spaces but also offer a gender-sensitive, political contemplation on the forces of striation and smoothing as well as a re-invention of space. The women in movement in Varda's films embody a transgression of stratified territories such as the image-orien
APA, Harvard, Vancouver, ISO, and other styles
8

Billingsley, Anne. "Rediscovering Paris, Rediscovering Identity: An Exploration of Sounds and Voice in Cléo from 5 to 7." Film Matters 10, no. 1 (2019): 7–15. http://dx.doi.org/10.1386/fm.10.1.7_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fort, Jeff. "Paris Centrifuge: Cléo de 5 à 7 in Black and White, or: The Ills of Colonialism." Telos 2021, no. 197 (2021): 79–100. http://dx.doi.org/10.3817/1221197079.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Reader, K. "Cleo de 5 a 7." French Studies 63, no. 4 (2009): 495–96. http://dx.doi.org/10.1093/fs/knp172.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

YU, Gina. "A Study on the process of variations from object to subject: in text Cléo de 5 à 7 (1962)." Cine forum 34 (December 31, 2019): 9–30. http://dx.doi.org/10.19119/cf.2019.12.34.9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Powrie, Phil. "Heterotopic Spaces and Nomadic Gazes in Varda: From Cléo de 5 à 7 to Les Glaneurs et la glaneuse." L'Esprit Créateur 51, no. 1 (2011): 68–82. http://dx.doi.org/10.1353/esp.2011.0009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Conway, Kelley. "““A New Wave of Spectators””: Contemporary Responses to Cleo from 5 to 7." Film Quarterly 61, no. 1 (2007): 38–47. http://dx.doi.org/10.1525/fq.2007.61.1.38.

Full text
Abstract:
ABSTRACT The cinéé-club was central to French fi lm culture in the 1950s and 60s. Analysis of cinéé-club programming, educational activities, and of questionnaires fi lled out at the premier of Agnèès Varda's Cleo from 5 to 7 reveals that the cinéé-club powerfully shaped viewers' tastes and viewing skills.
APA, Harvard, Vancouver, ISO, and other styles
14

Bertin-Maghit, Jean-Pierre, and Sylvie Lindeperg. "Clio de 5 a 7. Les actualites filmees de la Liberation: Archives du futur." Vingtième Siècle. Revue d'histoire, no. 71 (July 2001): 141. http://dx.doi.org/10.2307/3772558.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Foran, James, Angelina The, Pam Dixon, Marcel Devetten, and Mikkael Sekeres. "Phase I Study of Clofarabine with Standard-Dose Infusional Cytarabine (Ara-C) as Intensive Induction Therapy for Newly-Diagnosed De Novo Acute Myeloid Leukemia in Older Adults Age ≥60 Years." Blood 110, no. 11 (2007): 1831. http://dx.doi.org/10.1182/blood.v110.11.1831.1831.

Full text
Abstract:
Abstract Background The median age of AML is approximately 70 years, and the survival of older adults age ≥60 years remains poor with standard therapy. Clofarabine (CLO) has significant single agent activity in AML, and in vitro studies demonstrate synergy with Ara-C. We therefore performed a phase I study to determine the maximum tolerated dose (MTD) of CLO with standard dose Ara-C (100mg/m2/day D1-7 by 24hr continuous infusion) as AML induction therapy. CLO was administered daily × 5 days beginning D2 to allow for pharmacokinetic (PK) & pharmacodynamic (PD) studies. Methods Enrollment wa
APA, Harvard, Vancouver, ISO, and other styles
16

Faderl, Stefan, Guillermo Garcia-Manero, Varsha Gandhi, et al. "Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome." Blood 110, no. 11 (2007): 1455. http://dx.doi.org/10.1182/blood.v110.11.1455.1455.

Full text
Abstract:
Abstract Clofarabine (CLO) is an adenosine nucleoside analog with activity in adult acute myeloid leukemia (AML). Its activity in MDS is less well defined. To evaluate the activity and safety of CLO in MDS we designed two phase II studies with iv CLO and po CLO, respectively. Pts were eligible if they had MDS with ≥ 5% blasts, fell into IPSS intermediate-2 and high-risk groups, or had CMML. No prior intensive chemotherapy or high-dose cytarabine was allowed. Hematopoietic growth factor support was permitted. In the iv study pts were adaptively randomized to receive CLO 15 or 30 mg/m2 iv daily
APA, Harvard, Vancouver, ISO, and other styles
17

Faderl, Stefan, Guillermo Garcia-Manero, Farhad Ravandi, et al. "Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS)." Blood 112, no. 11 (2008): 222. http://dx.doi.org/10.1182/blood.v112.11.222.222.

Full text
Abstract:
Abstract Clofarabine (CLO) is a second generation deoxyadenosine nucleoside analog with activity in pts with acute myeloid leukemia (AML). Early reports also suggested activity in MDS, but the role of CLO in MDS has not been defined. To evaluate the activity and safety of CLO in MDS we designed two phase II studies of IV CLO and PO CLO, respectively. Pts were eligible with MDS and ≥5% blasts or IPSS intermediate-2 and high-risk, CMML, and RAEB-t by FAB. Hematopoietic growth factor support prior to and during the study was permitted. In the IV study pts were adaptively randomized (based on resp
APA, Harvard, Vancouver, ISO, and other styles
18

Barba, Pere, Antonia Sampol, María Calbacho, et al. "Clofarabine-Based Chemotherapy for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. the Spanish Experience." Blood 118, no. 21 (2011): 4246. http://dx.doi.org/10.1182/blood.v118.21.4246.4246.

Full text
Abstract:
Abstract Abstract 4246 Background: Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) have a very poor outcome with limited therapeutic options available. Clofarabine (Clo) is a second generation purine nucleoside analogue increasingly used in these patients, mainly in the pediatric setting. Aims: To evaluate the toxicity profile and outcome of Clo-based chemotherapy regimens used in adult ALL in the Spanish PETHEMA centers. Materials and Methods: Sixteen of the 22 PETHEMA centers to have used Clo in adult patients (≥16 years) with a definitive diagnosis of ALL (n=25) or lymp
APA, Harvard, Vancouver, ISO, and other styles
19

Sakaguchi, Kimiyoshi, and Hiroyoshi Takahashi. "2′-Deoxy-5-Azacytidine Enhances Cytotoxic Effect Of Other Anti-Leukemic Agents Synergistically In Acute Lymphoblastic Leukemia Cell Line." Blood 122, no. 21 (2013): 5564. http://dx.doi.org/10.1182/blood.v122.21.5564.5564.

Full text
Abstract:
Abstract Introduction Advances in chemotherapy have improved the outcome of childhood acute lymphoblastic leukemia (ALL). However, leukemia cells in refractory ALL are often resistant to anti-leukemic agents. Although recent studies have focused on the epigenetic changes in refractory leukemia, the relationship between the demethylating agent 2′-deoxy-5-azacytidine (decitabine, DAC) and ALL remains unclear. Here, we examine the combined effects of DAC and anti-leukemic agents such as clofarabine (CLO) and etoposide (ETO) on the ALL cell line CCRF-CEM. Methods and results In vitro drug sensitiv
APA, Harvard, Vancouver, ISO, and other styles
20

Yakovson, Elizabeth, and Sharon Snir. "Key Themes and Pictorial Phenomena in the Joint Drawings of 5 to 7-Year-Old Children and Their Mothers (Thèmes clés et phénomènes picturaux dans les dessins conjoints d’enfants de 5 à 7 ans et de leurs mères)." Canadian Art Therapy Association Journal 32, no. 1 (2019): 5–17. http://dx.doi.org/10.1080/08322473.2019.1580501.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

van Besien, Koen, Justin Kline, Lucy A. Godley, et al. "Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes." Blood 114, no. 22 (2009): 197. http://dx.doi.org/10.1182/blood.v114.22.197.197.

Full text
Abstract:
Abstract Abstract 197 Supported by an unrestricted grant from Genzyme Corporation. Fludarabine (Flu) melphalan-alemtuzumab is a well tolerated, reduced intensity conditioning regimen for HCT. Clofarabine (Clo), a second generation nucleoside analog with excellent activity in acute leukemia, might enhance disease control over Flu. We report outcomes of a completed phase I and ongoing phase II study of CMA conditioning for allogeneic peripheral blood HCT. Tacrolimus was administered as GVHD prophylaxis. For the phase I cohort, one pt was enrolled per dose level, until the first DLT or until 2 ha
APA, Harvard, Vancouver, ISO, and other styles
22

O'Donnell, Peter H., Federico Innocenti, Amittha Wickrema, et al. "Association of clofarabine (Clo)-associated GFR decline (GFRd) with dose and AUC." Journal of Clinical Oncology 30, no. 15_suppl (2012): e13120-e13120. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13120.

Full text
Abstract:
e13120^ Background: Clo, a nucleoside analog, is approved for pediatric ALL, but also has activity in AML. We conducted a ph I-II trial of clo-melphalan-alemtuzumab for allo transplant and found grade 3-5 renal toxicity in 16 of 74 patients, despite prolonging infusion time to reduce Cmax (BBMT 2011, Epub). Methods: Clo pharmacokinetics were analyzed in 65 pts (Clo doses 10-40 mg/m2, infusion time 1 or 3 hrs) of 74 pts; baseline GFR estimated by modified MDRD equation. Clo levels were drawn at 1, 1.5, 2, 3, 5, 7, 9 and 24 hrs following the 1st and 3rd (or 4th) dose. GFRd (in ml/min/m2) between
APA, Harvard, Vancouver, ISO, and other styles
23

Zheludev, A., Z. Honda, K. Katsumata, R. Feyerherm, and K. Prokes. "Field-induced commensurate long-range order in the Haldane-gap system Ni(C 5 H 14 N 2 ) 2 N 3 (ClO 4 )." Europhysics Letters (EPL) 55, no. 6 (2001): 868–73. http://dx.doi.org/10.1209/epl/i2001-00362-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Zeidan, Amer M., Hetty E. Carraway, Hyun Don Yun, Jacqueline M. Greer, and Judith E. Karp. "Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Leukemias,." Blood 118, no. 21 (2011): 3615. http://dx.doi.org/10.1182/blood.v118.21.3615.3615.

Full text
Abstract:
Abstract Abstract 3615 Background: The prognosis of patients with relapsed/refractory acute leukemias (RRAL) continues to be very poor, with a complete remission (CR) rate of ≤ 30% and a one-year disease-free survival of ≤ 10%. Consequently, there is no standard of care for the treatment of RRAL at the current time. Clofarabine (CLO) is a second-generation purine nucleoside analog that has shown activity against RRAL. The administration of CLO followed by Cyclophosphamide (Cy) enhances the DNA damage induced by Cy and increases AML/ALL blast apoptosis rates. We previously published a phase I s
APA, Harvard, Vancouver, ISO, and other styles
25

López-Gómez, Pablo, Leobardo Iracheta-Donjuan, Marbella Castellanos-Juárez, et al. "VARIACIÓN EN LA TOLERANCIA A DESINFECTANTES DE GENOTIPOS ÉLITE DE Coffea spp. CULTIVADOS in vitro." Revista Mexicana de Ciencias Agrícolas 2, no. 5 (2018): 645–57. http://dx.doi.org/10.29312/remexca.v2i5.1615.

Full text
Abstract:

 
 
 La embriogénesis somática puede ser afectada por la oxidación de los explantes al aplicar un método común de desinfección. En el Campo Experimental Rosario Izapa en 2006, se determinó la tolerancia a desinfectantes de explantes foliares de genotipos de café, mediante la dosis letal media (DL50) y con base en la tolerancia, se definió el desinfectante óptimo para el establecimiento aséptico. La DL50 de hipoclorito de sodio (NaClO), de hipoclorito de calcio (Ca[ClO]2) y la combinación de ambos, en explantes foliares de genotipos de Coffea canephora P. (INIFAP 95-
APA, Harvard, Vancouver, ISO, and other styles
26

Foster, Matthew Charles, Parag Kumar, Christine Marie Walko, et al. "Pharmacokinetic study of clofarabine: Oral bioavailability and the effect of cimetidine on renal clearance." Journal of Clinical Oncology 30, no. 15_suppl (2012): e13074-e13074. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13074.

Full text
Abstract:
e13074 Background: Clofarabine (CLO) is a purine analog with activity in myeloid neoplasms. Its oral dosing has been based on an estimated bioavailability (F) of 49% from uncontrolled trials. Animal models suggest that CLO renal clearance (CL) may be impaired in the presence of inhibitors of organic cation transporter-2 (OCT2), which mediates transport across the renal tubular basolateral membrane. We conducted a pharmacokinetic (PK) study of CLO to determine F, and examine the effect of the OCT2 inhibitor, cimetidine (CIM) on intravenous (IV) CLO. Methods: Patients had: 1) untreated AML ≥ 60
APA, Harvard, Vancouver, ISO, and other styles
27

Burnett, Alan K., William J. Kell, Robert K. Hills, et al. "The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective. A Pilot Study." Blood 108, no. 11 (2006): 1950. http://dx.doi.org/10.1182/blood.v108.11.1950.1950.

Full text
Abstract:
Abstract New treatment combinations are required for older patients with AML. Clofarabine is a novel nucleoside analogue which has been shown in several phase 2 studies in older patients to be active alone or in combination. Gemtuzumab Ozogamicin (GO) is also active in older patients and is currently undergoing evaluation in several randomised trials. As part of the proposed UK NCRI AML16 Trial for patients over 60 years we have undertaken a Pilot Trial to establish the feasibility combining standard dose Daunorubicin (D) (50mg/m2 days 1,3,5), Clofarabine (Clo) and GO (3mg/m2) as a novel combi
APA, Harvard, Vancouver, ISO, and other styles
28

Faderl, Stefan, Alessandra Ferrajoli, Farhad Ravandi-Kashani, et al. "Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage." Blood 108, no. 11 (2006): 159. http://dx.doi.org/10.1182/blood.v108.11.159.159.

Full text
Abstract:
Abstract Clofarabine (CLO) is a second-generation nucleoside analog with activity in acute leukemias. Whereas it has received FDA approval in children with relapsed acute lymphoblastic leukemia, the focus of clinical research in adults has shifted to AML. To improve single agent activity, various CLO combinations are being studied. Here we present the results of two dose-finding phase I studies, exploring combinations of CLO with idarubicin (IDA) [CI] and CLO+IDA+Ara−C [CIA] in patients (pts) with relapsed or refractory AML and high-risk MDS. Eligibility for CI required previous Ara-C and prim
APA, Harvard, Vancouver, ISO, and other styles
29

von Clarmann, T., M. Höpfner, S. Kellmann, et al. "Retrieval of temperature, H<sub>2</sub>O, O<sub>3</sub>, HNO<sub>3</sub>, CH<sub>4</sub>, N<sub>2</sub>O, ClONO<sub>2</sub> and ClO from MIPAS reduced resolution nominal mode limb emission measurements." Atmospheric Measurement Techniques 2, no. 1 (2009): 159–75. http://dx.doi.org/10.5194/amt-2-159-2009.

Full text
Abstract:
Abstract. Retrievals of temperature, H2O, O3, HNO3, CH4, N2O, ClONO2 and ClO from MIPAS reduced spectral resolution nominal mode limb emission measurements outperform retrievals from respective full spectral resolution measurements both in terms of altitude resolution and precision. The estimated precision (including measurement noise and propagation of uncertain parameters randomly varying in the time domain) and altitude resolution are typically 0.5–1.4 K and 2–3.5 km for temperature between 10 and 50 km altitude, and 5–6%, 2–4 km for H2O below 30 km altitude, 4–5%, 2.5–4.5 km for O3 between
APA, Harvard, Vancouver, ISO, and other styles
30

Chevallier, Patrice, Myriam Labopin, Stefanie Buchholz, et al. "Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT." Blood 118, no. 21 (2011): 3004. http://dx.doi.org/10.1182/blood.v118.21.3004.3004.

Full text
Abstract:
Abstract Abstract 3004FN2 Clofarabine (CLO), a second generation purine analogue, has demonstrated an efficient anti-leukemia activity while showing a favorable toxicity profile. The aim of our study was to analyse the results of CLO as part of the conditioning regimen prior to allo-SCT for the treatment of patients with AML or ALL. This retrospective multicenter report assessed the outcome of 90 patients who received a clofarabine-containing conditioning regimen allogeneic stem cell transplantation (allo-SCT) for AML (n=69) or ALL (n=21) between November 2006 and September 2010 and reported o
APA, Harvard, Vancouver, ISO, and other styles
31

Agarwal, Rajiv, Frederick L. Locke, Rangesh Kunnavakkam, et al. "A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes." Blood 118, no. 21 (2011): 496. http://dx.doi.org/10.1182/blood.v118.21.496.496.

Full text
Abstract:
Abstract Abstract 496 HCT may provide long-term disease control for patients (pts) with relapsed and/or refractory acute leukemias (AL) and advanced myelodysplastic syndromes (MDS). Active disease burden at HCT is associated with high relapse rates and poor long-term outcomes. We hypothesized tolerable intensification would be achieved safely by clofarabine cytoreduction followed by HCT conditioning at the nadir and would result in improved outcomes. We performed a prospective study (3/08 – 9/10) to examine the feasibility and efficacy of clofarabine (Clo) cytoreduction prior to HCT for relaps
APA, Harvard, Vancouver, ISO, and other styles
32

Zhang, Min, Tao Hu, Changyan Sun, Wenjun Li, and Zhidong Chang. "A Schiff base-based fluorescent probe for the quick detection of ClO− ions." Canadian Journal of Chemistry 98, no. 8 (2020): 403–7. http://dx.doi.org/10.1139/cjc-2019-0349.

Full text
Abstract:
A new Schiff base 2-hydroxy-5-[(2,7-dihydroxy-1-naphthyl)methylideneamino]benzoic acid (HNMB) has been designed and synthesized. HNMB was characterized by Fourier-transform infrared spectroscopy (FTIR), electrospray ionization mass spectrometry (ESI–MS), nuclear magnetic resonance spectrometry (NMR), and single crystal X-ray diffraction. Fluorescence spectra show that HNMB could be used as a “turn-on” probe to detect ClO− ions from other anions in DMSO/H2O (v/v = 1:1) with a fast response time of 10 s and a low detection limit of 3.6 × 10−7 mol/L. Moreover, the probe could work in a wide pH ra
APA, Harvard, Vancouver, ISO, and other styles
33

Faderl, Stefan, Guillermo Garcia-Manero, Zeev Estrov, et al. "Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome." Blood 114, no. 22 (2009): 118. http://dx.doi.org/10.1182/blood.v114.22.118.118.

Full text
Abstract:
Abstract Abstract 118 Clofarabine (CLO) is a second generation deoxyadenosine nucleoside analog with activity in patients (pts) with acute myeloid leukemia (AML). Early reports also suggestedactivity of iv CLO in myelodysplastic syndrome (MDS), but the role of CLO in MDS therapy remains largely undefined. Due to the molecular characteristics of CLO it can also be administered as an oral formulation with a bioavailability of around 50%. As an oral agent has obvious advantages over parenteral administrations, we designed a phase 2 study to evaluate the activity and safety of oral CLO in patients
APA, Harvard, Vancouver, ISO, and other styles
34

Nabhan, Chadi, Jacob David Bitran, Walter Fried, et al. "Clofarabine (CLO) Has Single Agent Activity in Relapsed and Refractory Non-Hodgkin Lymphoma (NHL) Including Rituximab (R)-Refractory Patients (pts)." Blood 114, no. 22 (2009): 921. http://dx.doi.org/10.1182/blood.v114.22.921.921.

Full text
Abstract:
Abstract Abstract 921 Background: CLO is a second generation nucleoside analogue with known activity in acute leukemia and myelodysplasia. As there is no standard therapy for refractory and transplant-ineligible relapsed NHL, and given the activity that purine analogues have in lymphoid malignancies, we sought to investigate the activity of CLO in this pt population regardless of histology. Methods: Eligible pts had measurable disease by CT and/or PET, ECOG performance status ≤ 2, and adequate renal, cardiac, liver, and bone marrow function (unless cytopenias were disease-related). CLO was giv
APA, Harvard, Vancouver, ISO, and other styles
35

Allen, A. M., and P. G. Guyenet. "Alpha 2-adrenoceptor-mediated inhibition of bulbospinal barosensitive cells of rat rostral medulla." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 265, no. 5 (1993): R1065—R1075. http://dx.doi.org/10.1152/ajpregu.1993.265.5.r1065.

Full text
Abstract:
Bulbospinal barosensitive neurons of the rostral ventrolateral medulla (RVLM cells; presumed sympathetic vasomotor premotor neurons) were recorded with iontophoretic electrodes in urethan-anesthetized rats. The majority of these cells were insensitive to intravenous clonidine (Clo; up to 20 micrograms/kg) and insensitive to iontophoretically applied Clo or alpha-methylnorepinephrine (alpha-MNE). These cells (n = 47 of 76) had a spinal conduction velocity of 4.1 +/- 0.2 m/s and a mean firing rate of 20 +/- 1 spikes/s. A second population (n = 29) was powerfully inhibited by intravenous Clo (5-1
APA, Harvard, Vancouver, ISO, and other styles
36

Castellani, John W., Andrew J. Young, David W. Degroot, et al. "Thermoregulation during cold exposure after several days of exhaustive exercise." Journal of Applied Physiology 90, no. 3 (2001): 939–46. http://dx.doi.org/10.1152/jappl.2001.90.3.939.

Full text
Abstract:
This study examined the hypothesis that several days of exhaustive exercise would impair thermoregulatory effector responses to cold exposure, leading to an accentuated core temperature reduction compared with exposure of the same individual to cold in a rested condition. Thirteen men (10 experimental and 3 control) performed a cold-wet walk (CW) for up to 6 h (6 rest-work cycles, each 1 h in duration) in 5°C air on three occasions. One cycle of CW consisted of 10 min of standing in the rain (5.4 cm/h) followed by 45 min of walking (1.34 m/s, 5.4 m/s wind). Clothing was water saturated at the
APA, Harvard, Vancouver, ISO, and other styles
37

Kadish, Karl M., Zhongping Ou, Xiaoyu Tan, Wataru Satoh, Yohsuke Yamamoto та Kin-ya Akiba. "Electrochemistry and spectral characterization of arsenic porphyrins with σ-bonded axial ligands: X-ray crystallographic analysis of [(OEP)As(F)2]+PF6−, [(OEP)As(CH3)(OCH3)]+ClO4− and [(OEP)As(C2H5)2]+PF6−". Journal of Porphyrins and Phthalocyanines 06, № 05 (2002): 325–35. http://dx.doi.org/10.1142/s1088424602000385.

Full text
Abstract:
The electrochemistry of nine arsenic(V) octaethylporphyrins is reported in benzonitrile or dichloromethane containing 0.1 M tetra-n-butylammonium perchlorate as supporting electrolyte and the results compared to data for phosphorus and antimony porphyrins containing a similar set of σ-bonded and/or anionic axial ligands. The investigated compounds are divided into three groups based on the nature of the axial ligands and are represented as [( OEP ) As ( R )( R ')]+ (group I), [( OEP ) As ( R )( X )]+ (group II) and [( OEP ) As ( F )2]+ (group III) where R and R’ = CH 3 or C 2 H 5, X = OH −, OC
APA, Harvard, Vancouver, ISO, and other styles
38

Froidevaux, Lucien, Douglas E. Kinnison, Michelle L. Santee, et al. "Upper stratospheric ClO and HOCl trends (2005–2020): Aura Microwave Limb Sounder and model results." Atmospheric Chemistry and Physics 22, no. 7 (2022): 4779–99. http://dx.doi.org/10.5194/acp-22-4779-2022.

Full text
Abstract:
Abstract. We analyze Aura Microwave Limb Sounder (MLS) monthly zonal mean time series of ClO and HOCl between 50∘ S and 50∘ N to estimate upper stratospheric trends in these chlorine species from 2005 through 2020. We compare these observations to those from the Whole Atmosphere Community Climate Model version 6 (WACCM6), run under the specified dynamics configuration. The model sampling follows the MLS coverage in space and local time. We use version 5 MLS ClO zonal mean daytime profiles and similarly binned daytime ClO model profiles from 32 to 1.5 hPa. For MLS HOCl, we use the version 5 off
APA, Harvard, Vancouver, ISO, and other styles
39

Agura, Edward D., R. Brian Berryman, Joseph W. Fay, Luis A. Pineiro, Estil A. Vance, and Mirjana Tadic-Ovcina. "Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies and Diseases." Blood 110, no. 11 (2007): 4954. http://dx.doi.org/10.1182/blood.v110.11.4954.4954.

Full text
Abstract:
Abstract Background: Nonablative transplant regimens are useful to treat patients who are elderly or too ill to undergo a full-intensity ablative allogeneic transplant regimen. However, this approach is limited by a higher relapse rate in some situations. We developed a novel conditioning regimen using the nucleoside analogue clofarabine (CLO) with busulfan (BU) to treat elderly patients with acute leukemia or high risk MDS who are not in remission or are at high risk of relapse. Methods: Five patients were enrolled on this single institution; phase II, IRB-approved trial, so far. The diagnose
APA, Harvard, Vancouver, ISO, and other styles
40

Gordon, Catherine, Amanda Ledbetter, and Gail Megason. "Clofarabine-Induced Remission in Relapsed Pediatric Acute Myelogenous Leukemia." Blood 112, no. 11 (2008): 4042. http://dx.doi.org/10.1182/blood.v112.11.4042.4042.

Full text
Abstract:
Abstract Despite improvements, the prognosis for children with recurrent or progressive acute myeloid leukemia (AML) remains poor; the 5-year relative survival rate for children under age 15 years is 54% (Jemal, et al., Ca Cancer J Clin 2008). Early relapse, defined as relapse within less than 18 months from time of initial diagnosis, is associated with a second CR rate of about 50% and an overall survival of 10% or less (Stahnke, K. et al. Leuk 1998). The second generation purine nucleoside analog clofarabine was designed to improve on the efficacy and safety of cladribine and fludarabine. In
APA, Harvard, Vancouver, ISO, and other styles
41

Faderl, Stefan, Guillermo Garcia-Manero, Farhad Ravandi, et al. "A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily × 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS)." Blood 120, no. 21 (2012): 3851. http://dx.doi.org/10.1182/blood.v120.21.3851.3851.

Full text
Abstract:
Abstract Abstract 3851 Clofarabine (CLO) is a nucleoside analog with activity in myeloid malignancies. We have previously reported an overall response rate (ORR) of 43% (CR rate 25%) in patients (pts) with higher-risk MDS treated with oral CLO at doses between 20 mg/m2 and 40 mg/m2 daily × 5 (S Faderl et al. J Clin Oncol 2010, 28: 2755). However, myelosuppression and infectious complications were frequent. We therefore developed a trial based on a Bayesian randomization design of CLO 10 mg vs 20 mg (flat dose) orally daily × 5 days with the objective to maintain reasonable efficacy and minimiz
APA, Harvard, Vancouver, ISO, and other styles
42

Zwaan, Christian M., Michael Dworzak, Thomas Klingebiel, et al. "Safety and Pharmacokinetics Of Clofarabine In Combination With High-Dose Cytarabine and Liposomal Daunorubicin In Pediatric AML: Results Of a Phase 1 Combination Study By The ITCC Consortium." Blood 122, no. 21 (2013): 2693. http://dx.doi.org/10.1182/blood.v122.21.2693.2693.

Full text
Abstract:
Abstract Introduction Relapsed/refractory pediatric AML has a poor prognosis despite salvage therapy including stem-cell transplantation. Chemotherapy using FLAG plus liposomal daunorubicine (FLAG-DNX) is currently considered the standard in 1strelapse in Europe (Kaspers et al, JCO 2013). FLAG is based on potentiation of cytarabine (Ara-C) by fludarabine (Flu) by increasing Ara-CTP levels. Clofarabine (CLO) is a novel purine nucleoside analog, designed to have improved efficacy. Methods We initiated an ongoing phase 1B dose-escalation study using a ‘3x3 design’ to define the optimal dose of CL
APA, Harvard, Vancouver, ISO, and other styles
43

Serrano, Josefina, Diana Buenasmañanas, P. Herrera, et al. "Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation (HCT) In Patients With Relapsed Or Refractory Acute Leukemia." Blood 122, no. 21 (2013): 3410. http://dx.doi.org/10.1182/blood.v122.21.3410.3410.

Full text
Abstract:
Abstract HCT is the only potentially curative approach that may provide long-term disease control for patients con relapsed and/or refractory acute leukemia (Re/Ref AL). However, active disease burden at HCT is associated with high relapse rates and dismal outcomes. Recently, promising results in this way have been reported using sequential treatment schedules. We performed a retrospective multicentre analysis to investigate the safety and efficacy of clofarabine (CLO) cytoreduction prior to HCT for Re/Ref AL. Spanish Agency Qualification was obtained (AAH-CLO-2013-01/EPA-OD). A total of 50 pa
APA, Harvard, Vancouver, ISO, and other styles
44

Karp, Judith E., Rebecca M. Ricklis, Jacqueline Greer, Janet Briel, and Mark J. Levis. "Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage." Blood 108, no. 11 (2006): 1963. http://dx.doi.org/10.1182/blood.v108.11.1963.1963.

Full text
Abstract:
Abstract CLO is a nucleoside analog with ribonucleotide reductase inhibitory activity. As such, CLO has the ability to impede repair of damaged DNA. We designed a Phase I clinical trial of CLO followed by CY for adults with refractory acute leukemias, with escalating doses of CLO (beginning10 mg/m2/day) and CY (beginning 400 mg/m2/day) days 1–3 and 8–10. The first CY dose was split between Day 0 and Day 1 at 200 mg/m2/dose to test the hypothesis that CLO could increase CY-induced DNA damage in leukemic blasts. Peripheral blood blasts were obtained prior to CY (Pre), at end Day 0 CY 2 hr infusi
APA, Harvard, Vancouver, ISO, and other styles
45

Wallace, Jennifer. "Varda, Cléo and Pomme in Paris: the figure of thechanteuseinCléo de 5 à 7andL’Une chante, l’autre pas." Studies in French Cinema 17, no. 1 (2016): 44–59. http://dx.doi.org/10.1080/14715880.2016.1237202.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Huang, Benjamin, Christopher C. Dvorak, Justin Wahlstrom, et al. "Risk Factors for Graft Failure with Busulfan/Fludarabine-Based Conditioning in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Nonmalignant Disorders." Blood 124, no. 21 (2014): 1155. http://dx.doi.org/10.1182/blood.v124.21.1155.1155.

Full text
Abstract:
Abstract Background: Allogeneic hematopoietic cell transplantation (aHCT) is curative for a number of pediatric nonmalignant disorders. Toxicities related to conditioning, failure of engraftment, and GVHD remain obstacles to successful transplantation for these patients. Since 2000, our institution has prospectively studied busulfan/fludarabine (Bu/Flu)-based conditioning regimens with a goal to reduce complications associated with myeloablative conditioning while maintaining adequate, stable donor-derived hematopoiesis. While overall survival has remained excellent, graft failure rates remain
APA, Harvard, Vancouver, ISO, and other styles
47

Gonzalez, Richard R., Samuel N. Cheuvront, Brett R. Ely, et al. "Sweat rate prediction equations for outdoor exercise with transient solar radiation." Journal of Applied Physiology 112, no. 8 (2012): 1300–1310. http://dx.doi.org/10.1152/japplphysiol.01056.2011.

Full text
Abstract:
We investigated the validity of employing a fuzzy piecewise prediction equation (PW) [Gonzalez et al. J Appl Physiol 107: 379–388, 2009] defined by sweat rate (msw, g·m−2·h−1) = 147 + 1.527·(Ereq) − 0.87·(Emax), which integrates evaporation required (Ereq) and the maximum evaporative capacity of the environment (Emax). Heat exchange and physiological responses were determined throughout the trials. Environmental conditions were ambient temperature (Ta) = 16–26°C, relative humidity (RH) = 51–55%, and wind speed ( V) = 0.5–1.5 m/s. Volunteers wore military fatigues [clothing evaporative potentia
APA, Harvard, Vancouver, ISO, and other styles
48

Durão Ferreira, Lúcia De Fátima, and Paula Moreira Baltar Bellemain. "Aire et de périmètre dans les manuels scolaires brésiliens à la transition entre l’école élémentaire et le collègeArea and perimeter in Brazilian textbooks at the transition from elementary school to college." Educação Matemática Pesquisa : Revista do Programa de Estudos Pós-Graduados em Educação Matemática 22, no. 4 (2020): 332–42. http://dx.doi.org/10.23925/1983-3156.2020v22i4p332-342.

Full text
Abstract:
RésuméCe travail, qui s’inscrit dans une recherche doctorale sur à la transition de la 5ème année (élèves de 10-11 ans) à la 6ème année (élèves 11-12 ans) de l’enseignement obligatoire brésilien, concerne l’analyse de manuels scolaires de 5ème et 6ème, à l'aide du filtre des grandeurs, de la notion de reprise et des niveaux de codétermination. La prise en charge des reprises proposée dans les manuels scolaires analysés ne paraît pas a priori suffisante pour assurer les conditions favorables à la transition entre les sous-niveaux et l’apprentissage des nouveaux objets étudiés en 6ème.Mots clés:
APA, Harvard, Vancouver, ISO, and other styles
49

Stuenkel, E. L., T. E. Machen, and J. A. Williams. "pH regulatory mechanisms in rat pancreatic ductal cells." American Journal of Physiology-Gastrointestinal and Liver Physiology 254, no. 6 (1988): G925—G930. http://dx.doi.org/10.1152/ajpgi.1988.254.6.g925.

Full text
Abstract:
The mechanisms underlying regulation of intracellular pH (pHi) by rat pancreatic duct cells were studied by use of the pH-sensitive, fluorescent, cytoplasmically trapped dye 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein (BCECF). Cells exhibited a mean pHi of 7.18 +/- 0.14 in bicarbonate-buffered medium, as calculated from the BCECF fluorescence ratio. Removal of extracellular Na (Nao) caused an intracellular acidification that was rapidly reversed by Na replacement and occurred independently of Clo. Amiloride (10(-3) M) reversibly blocked Na-dependent recovery after Na-free-induced acidifica
APA, Harvard, Vancouver, ISO, and other styles
50

Nabhan, Chadi, Walter Fried, Angel G. Galvez, Parameswaran Venugopal, Phillip Gozun, and Jacob D. Bitran. "Clofarabine (CLO) Is Active in Patients (pts) with Refractory and/or Relapsed Non-Hodgkin’s Lymphoma (NHL): A Phase I/II Study." Blood 110, no. 11 (2007): 4462. http://dx.doi.org/10.1182/blood.v110.11.4462.4462.

Full text
Abstract:
Abstract There is no known standard of care for pts with relapsed and/or refractory NHL who cannot undergo stem cell transplantation (SCT) or have relapsed after SCT. Such pts are candidates for new therapies. CLO is a novel nucleoside analogue with known activity in acute leukemia and myelodysplasia. Previous clinical trials with CLO have established safety and potential activity in a variety of tumors. We performed a phase I/II study of CLO in a heavily pretreated pt population with refractory and/or relapsed NHL regardless of cell type, histology, or grade. Eligible pts were adults over 18
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Cléo de 5 à 7' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography